0001209191-17-014007.txt : 20170223 0001209191-17-014007.hdr.sgml : 20170223 20170223183235 ACCESSION NUMBER: 0001209191-17-014007 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170221 FILED AS OF DATE: 20170223 DATE AS OF CHANGE: 20170223 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS CENTRAL INDEX KEY: 0000906709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943134940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 4154825300 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC DATE OF NAME CHANGE: 19980723 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS DATE OF NAME CHANGE: 19940303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lingnau Lutz CENTRAL INDEX KEY: 0001354179 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24006 FILM NUMBER: 17634145 MAIL ADDRESS: STREET 1: 15 INDIAN HOLLOW ROAD CITY: MENDHAM STATE: NJ ZIP: 07945 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-02-21 0 0000906709 NEKTAR THERAPEUTICS NKTR 0001354179 Lingnau Lutz C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 1 0 0 0 Common Stock 2017-02-21 4 M 0 30000 5.14 A 60450 D Common Stock 2017-02-21 4 S 0 30000 13.08 D 30450 D Stock Option 5.14 2017-02-21 4 M 0 30000 0.00 D 2012-09-30 2019-09-12 Common Stock 30000 0 D This transaction was made pursuant to a Rule 10b5-1 trading plan. This transaction was executed in multiple trades at prices ranging from $12.99 to $13.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Mark A. Wilson, Attorney-In-Fact 2017-02-23